|
|
|
|
|
|
by bedast
1209 days ago
|
|
|
Allowing the coupon to be used for the treatment of obesity is an implicit approval for the drug to be used in this way, and coupons are a form of marketing. Lilly cannot approve nor market this drug in a way that is off-label. This is why when Lilly talks about testing tirzepatide for weight loss, they say tirzepatide and not Mounjaro. Whenever you see articles mentioning Mounjaro for weight loss, these are statements not originating from Lilly. |
|
|